Header Logo

Connection

Clare Cutland to Immunization Schedule

This is a "connection" page, showing publications Clare Cutland has written about Immunization Schedule.
Connection Strength

1,533
  1. Vaccine Utilization and Timing of Administration in Pregnant Women: A South African Perspective. Pediatr Infect Dis J. 2025 Feb 01; 44(2S):S85-S89.
    View in: PubMed
    Score: 0,230
  2. Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study. Expert Rev Vaccines. 2025 Dec; 24(1):121-127.
    View in: PubMed
    Score: 0,230
  3. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 03 06; 397(10277):881-891.
    View in: PubMed
    Score: 0,175
  4. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial. Lancet Infect Dis. 2020 12; 20(12):1426-1436.
    View in: PubMed
    Score: 0,169
  5. Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa. Vaccine. 2020 02 28; 38(10):2350-2360.
    View in: PubMed
    Score: 0,163
  6. Immunogenicity and Safety of an Early Measles Vaccination Schedule at 6 and 12 Months of Age in Human Immunodeficiency Virus (HIV)-Unexposed and HIV-Exposed, Uninfected South African Children. J Infect Dis. 2019 09 26; 220(9):1529-1538.
    View in: PubMed
    Score: 0,159
  7. Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial. Expert Rev Vaccines. 2017 06; 16(6):641-656.
    View in: PubMed
    Score: 0,135
  8. Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials. Expert Rev Vaccines. 2020 12; 19(12):1177-1189.
    View in: PubMed
    Score: 0,043
  9. Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. Lancet HIV. 2020 02; 7(2):e91-e103.
    View in: PubMed
    Score: 0,040
  10. Measles seroprevalence in pregnant women in Soweto, South Africa: a nested cohort study. Clin Microbiol Infect. 2020 Apr; 26(4):515.e1-515.e4.
    View in: PubMed
    Score: 0,040
  11. Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy. Clin Infect Dis. 2017 Nov 13; 65(11):1897-1904.
    View in: PubMed
    Score: 0,035
  12. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. Lancet Infect Dis. 2016 08; 16(8):923-34.
    View in: PubMed
    Score: 0,031
  13. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatr Infect Dis J. 2013 Aug; 32(8):889-97.
    View in: PubMed
    Score: 0,026
  14. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine. S Afr Med J. 2011 Nov 28; 101(12):879-83.
    View in: PubMed
    Score: 0,023
  15. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis. 2009 Apr 15; 199(8):1168-76.
    View in: PubMed
    Score: 0,019
  16. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J. 2005 May; 24(5):410-6.
    View in: PubMed
    Score: 0,015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.